Wednesday - 14 November 2018

Antibody Patenting after Amgen v. Sanofi: a webinar on U.S. and European Perspectives

Mathys & Squire Of Counsel, Hazel Ford, will once again be joining a panel of patent attorneys in an encore webinar discussing: Antibody Patenting after Amgen v. Sanofi: U.S. and European Perspectives followed by a live question and answer session. 

The panel will examine the patentability requirements in the USPTO and EPO for claiming a broad genus of antibodies, recent case law that could impact those claims, and how to best protect antibody inventions in light of the latest developments. Topics of discussion will include: 

  • How broadly can the applicant claim? How much support is needed on a filing?
  • What are the differences between U.S. requirements and EPO requirements?
  • What is a sufficient description of a genus? Can functional language be included?
  • When can post-filing data be used?

Book your place by clicking here.

Thursday, December 20th 2018

1:00pm-2:30pm EST | 18:00 - 19:30 GMT

About the author

Hazel Ford

General Counsel

Hazel has extensive experience drafting patent applications and prosecuting them globally. She has particular experience of patent prosecution at the European Patent Office, in the fields of biotechnology (including antibodies, vaccines, genes and proteins), and pharmaceuticals (including drug formulation, diagnostics, and new administration regimes).